Study Describing the Hypertensive Population Treated With Telmisartan and Conditions of Use by Medical Practitioners and Patients
- Registration Number
- NCT02242851
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Primary objective: to characterize hypertensive patients treated for at least 1 month with Telmisartan (alone or in combination with other drugs) in order to define the beneficiary population (those actually receiving the treatment).
Secondary objectives:
* to describe the patients' blood pressure values (when self-monitored) and satisfaction with the treatment (ease of use, efficacy, safety) on the basis of a patient self-questionnaire, filled out 4 weeks after consultation.
* to compare the characteristics of the beneficiary population to those of the initial target population defined in the SPC (summary of product characteristics) for Telmisartan
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 5018
- Hypertensive patients treated with Telmisartan for at least one month, consulting a medical practitioner (for whatever reason)
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Hypertensive patients Telmisartan -
- Primary Outcome Measures
Name Time Method Characteristics of hypertensive patients Baseline, after 1 month of treatment Questionnaire to determine the beneficiary population
- Secondary Outcome Measures
Name Time Method Evaluation of patients satisfaction with treatment Up to 1 month Based on a patient 6-point self-questionnaire
Changes in blood pressure Up to 1 month Self-monitored by patient